SG11201600666SA - Medicament comprising anti-phospholipase d4 antibody - Google Patents

Medicament comprising anti-phospholipase d4 antibody

Info

Publication number
SG11201600666SA
SG11201600666SA SG11201600666SA SG11201600666SA SG11201600666SA SG 11201600666S A SG11201600666S A SG 11201600666SA SG 11201600666S A SG11201600666S A SG 11201600666SA SG 11201600666S A SG11201600666S A SG 11201600666SA SG 11201600666S A SG11201600666S A SG 11201600666SA
Authority
SG
Singapore
Prior art keywords
phospholipase
medicament
antibody
Prior art date
Application number
SG11201600666SA
Inventor
Tomohide Yamazaki
Mayuki Endo
Koji Ishida
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of SG11201600666SA publication Critical patent/SG11201600666SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
SG11201600666SA 2013-07-30 2014-07-30 Medicament comprising anti-phospholipase d4 antibody SG11201600666SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013158258 2013-07-30
PCT/JP2014/070661 WO2015016386A1 (en) 2013-07-30 2014-07-30 Medicament comprising anti-phospholipase d4 antibody

Publications (1)

Publication Number Publication Date
SG11201600666SA true SG11201600666SA (en) 2016-02-26

Family

ID=51493000

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201600666SA SG11201600666SA (en) 2013-07-30 2014-07-30 Medicament comprising anti-phospholipase d4 antibody
SG10201800592SA SG10201800592SA (en) 2013-07-30 2014-07-30 Medicament comprising anti-phospholipase d4 antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201800592SA SG10201800592SA (en) 2013-07-30 2014-07-30 Medicament comprising anti-phospholipase d4 antibody

Country Status (17)

Country Link
US (2) US20160168266A1 (en)
EP (1) EP3027656B1 (en)
JP (3) JP6431523B2 (en)
KR (1) KR102367760B1 (en)
CN (1) CN105745226B (en)
AU (1) AU2014297217B2 (en)
BR (1) BR112016002001B1 (en)
CA (1) CA2919736C (en)
DK (1) DK3027656T3 (en)
ES (1) ES2736324T3 (en)
HU (1) HUE044469T2 (en)
MX (1) MX2016001193A (en)
PL (1) PL3027656T3 (en)
RU (1) RU2709741C2 (en)
SG (2) SG11201600666SA (en)
TR (1) TR201910330T4 (en)
WO (1) WO2015016386A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102098413B1 (en) * 2012-01-31 2020-04-07 에스비아이 바이오테크 가부시키가이샤 Anti-phospholipase d4 antibody
WO2018013917A1 (en) * 2016-07-15 2018-01-18 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
JP7140367B2 (en) * 2018-05-31 2022-09-21 国立大学法人 東京大学 Analysis of soluble TLR7 in human-derived samples

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2149329C (en) * 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
EP1107978A1 (en) * 1998-08-24 2001-06-20 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
AU2002239505A1 (en) * 2000-12-07 2002-06-18 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of viral disease using 55092
JP2013052781A (en) 2011-09-05 2013-03-21 Tokai Rika Co Ltd Vehicle mirror device
KR102098413B1 (en) * 2012-01-31 2020-04-07 에스비아이 바이오테크 가부시키가이샤 Anti-phospholipase d4 antibody

Also Published As

Publication number Publication date
CN105745226B (en) 2020-03-06
PL3027656T3 (en) 2019-10-31
JP6431523B2 (en) 2018-11-28
RU2016106708A3 (en) 2018-03-30
WO2015016386A1 (en) 2015-02-05
CA2919736A1 (en) 2015-02-05
EP3027656A1 (en) 2016-06-08
ES2736324T3 (en) 2019-12-27
BR112016002001A2 (en) 2017-08-29
KR20160034934A (en) 2016-03-30
BR112016002001B1 (en) 2023-04-25
CN105745226A (en) 2016-07-06
EP3027656B1 (en) 2019-06-26
JP2019214621A (en) 2019-12-19
SG10201800592SA (en) 2018-03-28
JP6843449B2 (en) 2021-03-17
US20210130493A1 (en) 2021-05-06
HUE044469T2 (en) 2019-10-28
RU2709741C2 (en) 2019-12-19
CA2919736C (en) 2022-03-22
MX2016001193A (en) 2016-05-26
TR201910330T4 (en) 2019-07-22
KR102367760B1 (en) 2022-02-24
RU2016106708A (en) 2017-09-01
JP2019014759A (en) 2019-01-31
US20160168266A1 (en) 2016-06-16
AU2014297217B2 (en) 2020-01-16
JP2016534022A (en) 2016-11-04
AU2014297217A1 (en) 2016-02-18
DK3027656T3 (en) 2019-08-05

Similar Documents

Publication Publication Date Title
ZA201905426B (en) Drug combinations
SG10201708409VA (en) Medicament device
AU351520S (en) Inhaler
HRP20180684T1 (en) Drug combination
ZA201506252B (en) Syringe
AU352076S (en) Inhaler
HUE038547T2 (en) Inhaler
PL2978481T3 (en) Inhaler
LT3632373T (en) Inhaler
GB201300706D0 (en) Antibody
HUE053417T2 (en) Inhaler
HK1219961A1 (en) Human anti-ifn-alpha antibodies
LT3035887T (en) Inhaler
PL3016977T3 (en) Human anti-il-32 antibodies
EP2978473A4 (en) Auto-retractible syringe
SG11201600666SA (en) Medicament comprising anti-phospholipase d4 antibody
GB201320786D0 (en) Medicament
GB201301845D0 (en) Antibody delivery
GB201316662D0 (en) Pharmaceutical Combination
GB201310496D0 (en) Pharmaceutical combinations
GB201301723D0 (en) Pharmaceutical combinations